viral RNA synthesis, origin, and vaccines

In a recent study published in Current Research in Immunologyresearchers analyzed the characteristics of coronaviruses (CoVs) and novel CoV vaccine candidates. Study: Nature of viruses and pandemics: Coronaviruses. Image Credit: 3DJustincase/Shutterstock Background CoVs are a group of positive-strand, enveloped ribonucleic acid (RNA) viruses belonging to the Nidovirales order. There are four genera within the Orthocoronavirinae … Read more

Biological E’s Corbevax gets a boost, as govt allows mixing vaccines

The health ministry has approved Biological E’s Covid-19 vaccine Corbevax as the third shot after two doses of Covishield or Covaxin for all adults, clearing the decks for the first heterologous booster in India. So far, India was using the same vaccine as the third dose or precautionary shot (homologous boosting). Countries like the US … Read more

SARS-CoV-2 variants of concern and biological sex of patients affect molnupiravir efficacy

SARS-CoV-2 variants of concern and the biological sex of patients affect the efficacy of molnupiravir, the first orally available drug approved for outpatient use against COVID-19, according to a new study led by researchers in the Center for Translational Antiviral Research in the Institute for Biomedical Sciences at Georgia State University. SARS-CoV-2, the virus that … Read more

Disparities in United States COVID-19 vaccine distribution

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populations or their reduced access to health care facilities. But new research from University of California San Diego and collaborating institutions has identified an additional barrier to equity: whether or not each health care … Read more

COVID vaccine patch fights variants better than needles

A needle-free vaccine patch could better fight COVID-19 variants, such as Omicron and Delta, than a traditional needle vaccine according to a University of Queensland study in mice. A needle-free vaccine patch could better fight COVID-19 variants, such as Omicron and Delta, than a traditional needle vaccine according to a University of Queensland study in … Read more

A novel COVID-19 vaccine using modified bacterial DNA

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine, one that would, in theory, remain effective against new and emerging variants and could be taken as a pill, by inhalation or other delivery methods. Researchers at University of California San Diego School … Read more

IVI and Moderna sign memorandum of understanding for vaccine research and development

July 20, 2022, SEOUL, Republic of Korea – The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, signed a Memorandum of Understanding (MOU) today to establish a partnership … Read more

UTMB study shows vaccine rapidly protects against lethal Lassa fever

GALVESTON, TEXAS – Researchers at the University of Texas Medical Branch have achieved success with a new vaccine developed to fight Lassa Virus, a pathogen that causes Lassa fever. Lassa fever is lethal in humans and nonhuman primates with a mortality rate as high as 70% in hospitalized cases. As many as 500,000 people are … Read more

In survey, COVID-19 vaccine recipients report changes in menstrual bleeding – BIOENGINEER.ORG

CHAMPAIGN, Ill. – A new analysis of reports from more than 35,000 people offers the most comprehensive assessment so far of menstrual changes experienced by pre- and post-menopausal individuals in the first two weeks after receiving the COVID-19 vaccine. Published in the journal Science Advances, the study adds to the evidence that significant numbers of … Read more

NIH launches clinical trial of mRNA Nipah virus vaccine – BIOENGINEER.ORG

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine is manufactured by Moderna, Inc., (Cambridge, Massachusetts) and was developed in collaboration with NIAID’s Vaccine Research Center. It is based … Read more